Last checked at 11 Sep 2019 07:00
11 September 2019
Benchmark Holdings plc
("Benchmark" or the "Company")
Update on commercial licensing deals for non-core animal vaccines
Further to the Q3 Trading Update issued on 12 August 2019, the Company provides an update on the timing of the commercial licensing deals for its non-core animal vaccines.
Due to delays in discussions with third parties, a commercial licensing agreement is now not expected to be completed by the end of the Group's financial year ending 30 September 2019. A further announcement will be made in due course.
The Company is accelerating its programme of disposals and structural efficiencies and will provide an update on progress at its Q4 Trading Update in November.
Enquiries
For further information, please contact: |
|
Benchmark Holdings plc | Tel: 020 3915 1236 |
Peter George, Chairman Malcolm Pye, CEO |
|
Ivonne Cantu, Investor Relations |
|
|
|
|
|
Numis (Broker and NOMAD) | Tel: 020 7260 1000 |
James Black, Freddie Barnfield, Freddie Naylor-Leyland
|
|
|
|
MHP Communications | Tel: 020 3128 8742 |
Katie Hunt / Reg Hoare / Alistair de Kare-Silver benchmark@mphc.com
About Benchmark Benchmark's mission is to enable food producers to improve their sustainability and profitability.
We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (artemia), sea lice treatments, training and data management tools. Find out more at www.benchmarkplc.com